FDA Authorizes 24 VELO Nicotine Pouches: What It Means for You (November 2026)

Big news for VELO fans. On 30 October 2026, the US Food and Drug Administration announced that the FDA authorizes 24 VELO nicotine pouches for sale in the United States. It is the first time BAT's pouch brand has received FDA marketing authorization, and it takes the total number of FDA-authorized pouches to 67.

Want the closest European match to the new US line? Try VELO Sour Lime Mini, a low-strength 4.2 mg mini pouch with the same lime flavour, for €5.95.

Key Takeaways

• 24 VELO products authorized: 8 flavour and format combinations in 3 packaging types, all 4 mg.
• US total now 67: ZYN (PMI), on! (Altria) and now VELO (BAT).
• Lower toxicants: the FDA found lower levels of harmful constituents than cigarettes and smokeless tobacco.
• Not "FDA approved": authorization means legal to sell to adults 21+ in the US, not safe.
• In Europe, nothing changes legally, but all eyes are on the EU tax vote on 9 November.

What Exactly Did the FDA Authorize?

According to the FDA's announcement, the authorized products are made by Modoral Brands Inc., BAT's US pouch business, under the VELO brand. Every product is listed at 4 mg of nicotine, and they were authorized through the premarket tobacco product application (PMTA) pathway.

Why 24 Products and Not 8?

Each of those 8 products comes in three different types of packaging, and the FDA counts each one separately. The agency says packaging can greatly affect stability, shelf life, moisture and safety, so it is part of the review. All three packaging types use certified child-resistant designs, something the FDA has been pushing pouch makers to adopt to prevent accidental poisoning in young children.

What the FDA Found

The FDA's evaluation found that the 24 products contain lower levels of harmful and potentially harmful constituents (HPHCs) than cigarettes and smokeless tobacco, and many were too low to even measure. Notably, the pouches had no measurable levels of several carcinogens linked to oral cancer in smokeless tobacco users.

The FDA also stressed one key point: adults who smoke need to switch completely. In its words, dual use "does not provide the same degree of health benefit." And as the FDA's official list of authorized pouches says, authorization does not mean a product is safe or "FDA approved." All tobacco and nicotine products are harmful and potentially addictive.

The Scoreboard: 67 FDA-Authorized Pouches

Until last week, only two companies had FDA-authorized pouches. VELO's entry makes it a three-way race. Here is how the 67 break down, based on Tobacco Insider's industry roundup:

The momentum has been fast. In August the FDA authorized 11 ZYN ULTRA pouches at 9 mg and 11 mg, bringing the total to 43 at the time. Add 24 VELOs, and the list has grown by more than half in a few months. For more on ZYN's US moves, read our recap of PMI's Q3 2026 results and the new 20-pouch ZYN cans.

The Pilot Program Behind the Speed-Up

The VELO products were reviewed under the FDA's nicotine pouch pilot program, launched in September 2025. Its first decisions, six on! PLUS products, came in record time, just three months after scientific review began.

That is a big change. A US government watchdog report from the Government Accountability Office found that, from 2018 to 2025, the FDA took an average of 507 days to finish reviewing tobacco product applications, and almost 132,000 applications were still waiting at the end of 2025. The GAO says the pilot is too new to know whether it will fix delays for good, but the steady stream of pouch authorizations this year suggests it is working for this category.

What It Means for Pouch Users in Europe

Short answer: legally, nothing changes in Europe. FDA decisions only apply in the US. EU countries still set their own pouch rules, from Sweden's open market to outright bans elsewhere. Check where things stand in our country-by-country guide to nicotine pouch laws in Europe.

But it still matters, for three reasons:

1. Science on the record. A major regulator has again found pouches have far lower toxicant levels than cigarettes. That carries weight in European debates.
2. Brand confidence. VELO is now FDA-authorized alongside ZYN, which strengthens its position as a global brand.
3. Timing. The news lands days before EU finance ministers meet on 9 November to discuss a minimum EU tax on pouches.

The EU Tax Vote on 9 November

As DSV Europa reports, the EU wants common minimum taxes on nicotine pouches for the first time, but tax decisions need unanimity, and Sweden has objected to the pouch rate. Whether ministers can agree on 9 November is still uncertain. Get the full background in our explainer on the EU nicotine pouch tax vote. We will report the result as soon as it is in.

European VELO Picks Closest to the New US Line

The US Mini Pouch range is not sold in the EU, but European VELO has its own low-strength mini pouches that hit a similar spot:

See the full range in our VELO collection, or read our VELO review with every flavour ranked. Torn between the two big names? Our ZYN vs VELO comparison breaks it down. And if you want low strength from other brands, ZYN, LOOP and XQS all have lighter options.

Other Pouch News This Week

• Altria's on! keeps growing. Nicotine pouches made up 61.2% of the US oral tobacco category in Q3 2026, up 5.8 points year on year, as Altria rolled out on! PLUS 12 mg nationwide.
• US use is rising among adult tobacco users. A University of Cincinnati survey found current pouch use among adult tobacco users rose from 3% to 10.2% between 2021 and 2024, reports Medical Xpress.
• Retailers see the VELO move as big. US convenience store body NACS covered the decision as a key update for retailers stocking pouches.

Why 4 mg Matters

All 24 newly authorized VELOs are 4 mg, a lighter strength. That fits a broader pattern in US authorizations, which have focused on lower and mid strengths. If you are new to pouches or cutting down, starting low is smart. Our beginner's guide to nicotine pouches and strength guide will help you find your level.

FAQ: FDA and VELO Nicotine Pouches

Did the FDA approve VELO nicotine pouches?

Not quite. On 30 October 2026 the FDA authorized the marketing of 24 VELO Mini Pouch and Mini Pouch 2 products, all 4 mg. Authorization means they can be legally sold in the US to adults 21+. The FDA is clear that it does not mean the products are safe or FDA approved.

Which VELO flavours did the FDA authorize?

Crema, Lime, Orange Crema and Passion Fruit in VELO Mini Pouch, plus Crema, Lime, Orange Crema and Cinnamon in VELO Mini Pouch 2. Each comes in three packaging types, which makes 24 products.

How many nicotine pouches has the FDA authorized in total?

67 as of early November 2026, from three makers: PMI (ZYN), Altria (on! and on! PLUS) and BAT (VELO).

Does the FDA decision change anything in Europe?

Not legally. FDA decisions only apply in the US. In Europe, pouch rules are still set country by country, and EU finance ministers are due to discuss an EU-wide minimum tax on pouches on 9 November 2026.

Can I buy the same VELO pouches in Europe?

The exact US Mini Pouch line is not sold in the EU, but European VELO has similar 4 mg mini options, like VELO Sour Lime Mini and VELO Dark Cherry Mini.

Final Thoughts

The FDA's decision to authorize 24 VELO nicotine pouches is a milestone for BAT and for the category. It adds a third major brand to the US authorized list and adds more regulator-backed data showing pouches have far lower toxicant levels than cigarettes. In Europe, the next big moment is the 9 November tax vote, and we will be watching.

Want to try VELO's lighter side now? Grab VELO Sour Lime Mini or VELO Dark Cherry Mini. Orders over €99 ship free, and new subscribers get 10% off their first order. Sign up and we will email you the code.

Nicotine pouches are for adults who already use nicotine. They contain nicotine, which is addictive.